nature portfolio

| Corresponding author(s): | PJ Dodd |
|----------------------------|-------------|
| Last updated by author(s): | Mar 6, 2023 |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| _ | | | | |
|-----|----|----|---------------|------|
| C - | トつ | t١ | ct | ics |
| | п | | > 1 | 11 > |

| FUI (| an statistical analyses, commit that the following items are present in the figure regend, table regend, main text, or Methods section. |
|-------------|--|
| n/a | Confirmed |
| | \square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| \boxtimes | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| \boxtimes | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| \boxtimes | A description of all covariates tested |
| \boxtimes | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| \boxtimes | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> |
| | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| \boxtimes | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| \boxtimes | Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |
| | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |

Software and code

Policy information about availability of computer code

Data collection

The following R packages are used: here, data.table, ggplot2, lhs, glue, ggthemes, scales, ggpubr, ggrepel, grid, patchwork, odin, GGally, metafor, reticulate, ggnewscale. The following Python package was used: zeus. These are all open source and available via standard packaging commands for R and Python (e.g. install.packages for R and pip3 for Python)

Data analysis

Analysis is open source using R, Python, C++, and bash. All code and library dependencies are at https://github.com/petedodd/estevez, and the specific version is archived at doi:10.5281/zenodo.7701274 and cited in the article.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

Data are routinely available and included in the GitHub repository with processing scripts. This is at https://github.com/petedodd/estevez, and the specific version is archived at doi:10.5281/zenodo.7701274 and cited in the article.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

| Reporting on sex and gender | We only use aggregate data and did not recruit |
|-----------------------------|--|
| Population characteristics | See above |
| Recruitment | See above |
| Ethics oversight | See above |
| | |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

| Please select the one belo | ow that is the best fit for your research | . If you are i | ot sure, read the | appropriate sections before making your selection. | |
|----------------------------|---|----------------|--------------------|--|--|
| X Life sciences | Behavioural & social sciences | Ecolo | gical, evolutionar | y & environmental sciences | |

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | We have included values of n where samples from the posterior were used to calculate quantities. Typically n=300 was used as this was commensurate with our MCMC effective sample size; sought for in order that Monte Carlo errors in proportions were of the order 1%. |
|-----------------|--|
| Data exclusions | No data were excluded |
| Replication | Subject to pseudo-random number seeds, computational results yield the same answer each time so replication is not applicable. |
| Randomization | Because all experiments are in silico, there is no true randomness in results and no unmeasured explanatory variables, and so randomization is not applicable. |
| Blinding | Blinding was not relevant or possible because data needed to be gathered and linked for each specific country. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| | | ر |
|---|---------------|----------|
| | Ω | ر |
| | 7 | + |
| | \subseteq | |
| | Ξ | ₹ |
| | a | Š |
| | ٠, | |
| | 7 | ٦ |
| | ⊱ | ≺ |
| | C | J |
| | Ξ | ٦ |
| | ⊆ | 1 |
| | c | ₹ |
| | \leq | <u> </u> |
| | Ħ | F |
| | \mathcal{C} |) |
| | ` | 1 |
| | | |
| | | |
| | | ٦ |
| | a | ٦ |
| | | |
| | | ₹ |
| | ζ | 5 |
| | | 5 |
| | | 5 |
| | | |
| | 2 | |
| | | |
| - | 2 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | 3 |
| | | 3 |

| Ē | | |
|-------------|---|----|
| Z | | |
| | | |
| Ξ | | |
| | | |
| $\bar{\nu}$ | ٤ | |
| C | | ١. |
| N | | |
| = | 2 | ۲ |

| iviateriais & experimental systems | | Methods | | |
|------------------------------------|-------------------------------|-------------|------------------------|--|
| n/a | Involved in the study | n/a | Involved in the study | |
| \boxtimes | Antibodies | \boxtimes | ChIP-seq | |
| \boxtimes | Eukaryotic cell lines | \times | Flow cytometry | |
| \boxtimes | Palaeontology and archaeology | \boxtimes | MRI-based neuroimaging | |
| \boxtimes | Animals and other organisms | | | |
| \boxtimes | Clinical data | | | |
| \boxtimes | Dual use research of concern | | | |